VTU Technology currently offers a very broad and comprehensive Pichia pastoris expression platform and the deal grants Biomay access to VTU’s Pichia pastoris protein expression technology.
Under the deal, Biomay will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens.
VTU Technology Business Development head Thomas Purkarthofer said: "VTU’s Pichia platform has already been utilized for the production of a wide range of different recombinant proteins with licenses granted to companies from diverse industries."
The deal will see VTU Technology receive royalties based on Biomay´s worldwide sales of these newly produced recombinant allergens.
VTU’s Pichia platform enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes.
Biomay chief operating officer Hans Huber said: "For Biomay, this technology cooperation with VTU is an excellent option for manufacturing of allergens being difficult to express.
"Thereby, we recently managed to produce and offer for sale the major allergen from ragweed pollen, Amb a 1, as a recombinant product."